Table 1.
General characteristic of the included studies.
| Study | Country | Case Number | Case Age (Mean ± SD) | Case Gender Men, (%) | Antipsoriatic Therapy | Control Number | Control Age (Mean ± SD) | Control Gender Men, (%) | NOS |
|---|---|---|---|---|---|---|---|---|---|
| Yeh et al., 2019 [19] | Taiwan | 34 | SEC: 51 ± 12 UST: 48.4 ± 12.7 |
25 (73.5%) | No treatment except for topical agents * | 12 | 48.4 ± 13.3 | 10 (83.3%) | 8 |
| Shapiro et al., 2019 [20] | Israel | 24 | 52.7 ± 11.6 | 16 (66.7%) | Topical treatment (22) Biologics (2) |
22 | 43.9 ± 12.7 | 16 (72.7%) | 8 |
| Huang et al., 2019 [21] | China | 35 | 52.1 ± 3.0 | 22 (62.9%) | NR | 27 | 52.9 ± 1.5 | 16 (59.3%) | 6 |
| Hidalgo-Cantabrana et al., 2019 [22] | Spain | 19 | 49 ± 11 | 12 (63.2%) | No treatment except for topical corticosteroids | 20 | 43 ± 11 | 5 (25%) | 6 |
| Chen et al., 2018 [23] | Taiwan | 32 | 42.8 ± 12.6 | 25 (78.1%) | Phototherapy (8) DMARDs/ Biologics (20) |
64 | 44.2±10.8 | 50 (78.1%) |
7 |
| Codoner et al., 2018 [24] | Spain | 52 | 41.2 ± 14.4 | 25 (48.1%) | NR | NR | NR | NR | 4 |
| Tan et al., 2018 [25] | China | 14 | 47.5 ± 4.7 | 10 (71.4%) | NR | 14 | 40.4 ± 2.5 | 8 (57.1%) | 7 |
| Eppinga et al., 2016 [26] | Netherlands | 29 | 46 ± 14.0 | 12 (41.4%) | No treatment (27) DMARDs (2) |
33 | 41 ± 14.9 | 10 (30.3%) | 6 |
| Massallat et al., 2016 [27] | Egypt | 45 | 42.3 ± 10 | 18 (40%) | NR | 45 | 44.2 ± 7.1 | 20 (44.4%) | 8 |
| Scher et al., 2015 [28] | US | 15 | 39.4 | 7 (46.7%) | No systemic treatment | 17 | 42.2 | 6 (35.3%) | 6 |
SD—standard deviation; NOS—the Newcastle-Ottawa Scale; NR—not reported; DMARDs—disease-modifying antirheumatic drugs; *—microbiome analysis before biological treatment.